반응형
| 구분 | 보고서(영문) |
| 제약/바이오/ 임상시험 (16건) |
Interim Results of IGNAZ Trial Sheds Positive Light on Felzartamab for IgAN |
| Verona Prepares for Anticipated US Launch of Ensifentrine for COPD in Q3 2024 | |
| Clinical Trial Landscape for Sub-Saharan Africa | |
| Influx of Adoptive Cell Therapies May Be on the Horizon | |
| Thematic Intelligence: The State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) | |
| Clinical Trials: Adoptive Cell Therapy | |
| ASCO 2024: Merus Charging Ahead After Positive Results for Petosemtemab in HNSCC | |
| ASCO 2024: Moderna’s Cancer Vaccine Poised to Redefine the Melanoma Landscape | |
| ASCO 2024: Akeso’s Bispecific Ivonescimab Facing a Rocky Road Ahead in NSCLC | |
| ASCO 2024: Survival Benefit for Subcutaneous Formulated Rybrevant | |
| ASCO 2024: Enhertu is Aiming to Replace Herceptin in First-Line Metastatic Breast Cancer | |
| ASCO 2024: Can Ambrx’s Novel ADC Break into the Metastatic Breast Cancer Market? | |
| ASCO 2024: Tagrisso to Become New Standard of Care for Unresectable Stage III EGFR-mutated NSCLC | |
| ARVO Conference Unveils Positive Vabysmo Data | |
| AIFA’s Horizon Scanning 2024 Predictions Suggest Preparations for an Influx of ATMPs | |
| Bio/Pharmaceutical Outsourcing Report, May 2024 | |
| 질환별 (10건) |
Climate Change May Aggravate Major Neurological Disorders, Including Multiple Sclerosis |
| ASCO 2024: Practice-Changing Win for Opdivo Combo in Neoadjuvant Melanoma | |
| Attention Deficit Hyperactivity Disorder (ADHD): Opportunity Assessment and Forecast 2022-2032 | |
| Amyotrophic Lateral Sclerosis: Opportunity Assessment and Forecast 2019-2029 - Update | |
| Androgenic Alopecia: Competitive Landscape | |
| Insights on May: Osteoporosis Awareness & Prevention Month | |
| Breyanzi Battles CAR-T Rivals with Back-to-Back Approvals in Lymphoma | |
| MELAS Syndrome: Competitive Landscape | |
| Genital Herpes: Competitive Landscape | |
| 7MM ADHD Market Forecast to Decline by $1 Billion Between 2022 and 2032 | |
| 컨퍼런스/ 심포지엄/ 학회/기타 (2건) |
Manufacturing Inspections Down in China Amid Arrest Fears and No Access |
| AbbVie’s Strong Immunology Portfolio Forecast to Combat Humira Losses |
반응형
'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글
| 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 7.5. (금) (0) | 2024.09.15 |
|---|---|
| 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 6.20. (목) (0) | 2024.09.15 |
| 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 5.24. (금) (0) | 2024.09.15 |
| 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 5.10. (금) (0) | 2024.09.15 |
| 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 4.24. (수) (0) | 2024.09.15 |